Breast cancer treatments by AstraZeneca (AZ)/Daiichi Sankyo and Gilead are grabbing headlines at the annual meeting of the American Society of Clinical Oncology this week. Source: Drug Industry Daily
Novartis confirmed Monday it was the victim of a cyberattack that ended in stolen data but maintained the hackers didn’t get away with any sensitive information. Source: Drug Industry Daily
In a stunning mid-study analysis of 12 patients, GlaxoSmithKline’s anti-PD-1 antibody Jemperli (dostarlimab) completely eradicated locally advanced rectal tumors in every patient, sparing them life-altering surgery and causing minimal side…
The FDA issued a warning letter to Grimann, an over-the-counter (OTC) drug manufacturer located near Mexico City, for failure to comply with drug registration and listing requirements. Source: Drug Industry…
Johnson & Johnson’s (J&J) and AbbVie’s blockbuster cancer drug Imbruvica (ibrutinib) plus chemotherapy significantly slashed cancer spread in older patients suffering from mantle cell lymphoma (MCL) in a phase 3…
Bristol Myers Squibb (BMS) is buying clinical-stage oncology-focused Turning Point Therapeutics for $4.1B, the companies announced Friday. Source: Drug Industry Daily
Novavax goes before FDA’s Vaccines and Related Biologics Advisory Committee this week, seeking Emergency Use Authorization of its COVID-19 vaccine. Source: Drug Industry Daily
Bristol Myers Squibb’s Orencia (abatacept) and Janssen’s Remicade (infliximab) reduced the risk of death among patients hospitalized with COVID-19 by around 40 percent, according to a study commissioned by the National…
Pfizer and BioNTech hit back against Alnylam Pharmaceuticals’ claims alleging their COVID-19 vaccine infringed on Alnylam’s patent for lipid-nanoparticle delivery (LNP) technology. Source: Drug Industry Daily
Nephron Pharmaceuticals of South Carolina has issued a voluntary recall of about 2 million doses of its medicines after an FDA inspection found a “lack of assurance of sterility” across…